Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. more
Time Frame | AXSM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.99% | -2.27% | -0.57% |
1-Month Return | -7.9% | -3.96% | 1.21% |
3-Month Return | -3.81% | -9.7% | 7.57% |
6-Month Return | 24.26% | -3.37% | 11.45% |
1-Year Return | 21.04% | 3.71% | 28.48% |
3-Year Return | 176.8% | 3.8% | 29.52% |
5-Year Return | 92.56% | 39.78% | 90.66% |
10-Year Return | 930.89% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 8.82M | 50.04M | 270.60M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.26,"profit":true},{"date":"2022-12-31","value":18.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 37.33K | 77.72K | 1.16M | 5.20M | 26.07M | [{"date":"2019-12-31","value":0.14,"profit":true},{"date":"2020-12-31","value":0.3,"profit":true},{"date":"2021-12-31","value":4.43,"profit":true},{"date":"2022-12-31","value":19.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (37.33K) | (77.72K) | (1.16M) | 44.84M | 244.53M | [{"date":"2019-12-31","value":-0.02,"profit":false},{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":-0.47,"profit":false},{"date":"2022-12-31","value":18.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | - | (13.10%) | 89.61% | 90.37% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-14.5,"profit":false},{"date":"2022-12-31","value":99.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 67.11M | 99.09M | 124.71M | 221.34M | 476.36M | [{"date":"2019-12-31","value":14.09,"profit":true},{"date":"2020-12-31","value":20.8,"profit":true},{"date":"2021-12-31","value":26.18,"profit":true},{"date":"2022-12-31","value":46.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (67.25M) | (99.14M) | (124.71M) | (176.50M) | (231.82M) | [{"date":"2019-12-31","value":-6724509700,"profit":false},{"date":"2020-12-31","value":-9914132800,"profit":false},{"date":"2021-12-31","value":-12470693000,"profit":false},{"date":"2022-12-31","value":-17650082500,"profit":false},{"date":"2023-12-31","value":-23182500000,"profit":false}] |
Total Non-Operating Income/Expense | (2.34M) | (6.38M) | (11.39M) | (14.67M) | (12.91M) | [{"date":"2019-12-31","value":-233962600,"profit":false},{"date":"2020-12-31","value":-637868800,"profit":false},{"date":"2021-12-31","value":-1139212400,"profit":false},{"date":"2022-12-31","value":-1466924700,"profit":false},{"date":"2023-12-31","value":-1290600000,"profit":false}] |
Pre-Tax Income | (68.35M) | (102.90M) | (130.40M) | (187.13M) | (238.28M) | [{"date":"2019-12-31","value":-6834518600,"profit":false},{"date":"2020-12-31","value":-10290060000,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23827800000,"profit":false}] |
Income Taxes | 1.34M | 2.49M | 4.54M | 10.63M | 960.00K | [{"date":"2019-12-31","value":12.62,"profit":true},{"date":"2020-12-31","value":23.4,"profit":true},{"date":"2021-12-31","value":42.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.03,"profit":true}] |
Income After Taxes | (69.69M) | (105.39M) | (134.94M) | (197.77M) | (239.24M) | [{"date":"2019-12-31","value":-6968684100,"profit":false},{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}] |
Income From Continuous Operations | (68.35M) | (102.95M) | (130.40M) | (187.13M) | (239.24M) | [{"date":"2019-12-31","value":-6834518600,"profit":false},{"date":"2020-12-31","value":-10295417800,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (69.69M) | (105.39M) | (134.94M) | (197.77M) | (239.24M) | [{"date":"2019-12-31","value":-6968684100,"profit":false},{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}] |
EPS (Diluted) | (2.00) | (2.73) | (3.47) | (4.57) | (5.20) | [{"date":"2019-12-31","value":-200,"profit":false},{"date":"2020-12-31","value":-273,"profit":false},{"date":"2021-12-31","value":-347,"profit":false},{"date":"2022-12-31","value":-457,"profit":false},{"date":"2023-12-31","value":-520,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AXSM | |
---|---|
Cash Ratio | 1.67 |
Current Ratio | 2.44 |
Quick Ratio | 2.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AXSM | |
---|---|
ROA (LTM) | -26.44% |
ROE (LTM) | -171.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AXSM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.83 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AXSM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 13.99 |
P/B | 49.23 |
Price/FCF | NM |
EV/R | 13.11 |
EV/Ebitda | NM |
PEG | NM |
Axsome Therapeutics Inc (AXSM) share price today is $90.1
Yes, Indians can buy shares of Axsome Therapeutics Inc (AXSM) on Vested. To buy Axsome Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AXSM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Axsome Therapeutics Inc (AXSM) via the Vested app. You can start investing in Axsome Therapeutics Inc (AXSM) with a minimum investment of $1.
You can invest in shares of Axsome Therapeutics Inc (AXSM) via Vested in three simple steps:
The 52-week high price of Axsome Therapeutics Inc (AXSM) is $105. The 52-week low price of Axsome Therapeutics Inc (AXSM) is $64.11.
The price-to-earnings (P/E) ratio of Axsome Therapeutics Inc (AXSM) is
The price-to-book (P/B) ratio of Axsome Therapeutics Inc (AXSM) is 49.23
The dividend yield of Axsome Therapeutics Inc (AXSM) is 0.00%
The market capitalization of Axsome Therapeutics Inc (AXSM) is $4.74B
The stock symbol (or ticker) of Axsome Therapeutics Inc is AXSM